Merkel Cell Carcinoma of SkinVIRASKINNCT06780475
Validation of in Vitro Method for Anti-MCPyV Immunotherapy on Patients With Cutaneous Merkel Cell Carcinoma
An observational study of Merkel Cell Carcinoma of Skin, run by Assistance Publique - Hôpitaux de Paris at 1 site in France.
Trial summary
The aim of the study is to test and validate in vitro a cell therapy approach for MCPyV+ Merkel Cell Carcinoma patients. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Merkel Cell Carcinoma of Skin
- How many people
- 15 participants
- Where
- 1 siteFrance
- Study dates
- 27 May 2025to May 2027
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: Adult patients of Merkel cell carcinoma of skin, ongoing for local treatment, systemic treatment, complementary treatment or with an active follow-up beside dermatologist.
Who may be able to join
- Patients >= 18 years old;
- Diagnosed with Merkel cell carcinoma of skin, ongoing for local treatment, systemic treatment, complementary treatment or an active follow-up;
- Informed for the study and no-opposed for participation;
- Affiliated with a social security scheme or in an equivalent situation.
Who cannot join
- Patients ongoing another interventional clinical trial;
- Patients under guardianship or trusteeship;
- Pregnancy or breastfeed;
- Patients refusal.
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
Yassine Taoufik, MD, PhD contact
France1 site, 1 recruiting
- Recruiting
Dermato-oncology Department, Ambroise Paré Hospital, APHP
Boulogne-Billancourt, 92100
About this study
Official title: Validation of in Vitro Method for Anti-MCPyV Immunotherapy on Patients With Merkel Cell Carcinoma of Skin
The aim of the study is to test and validate in vitro a cell therapy approach for MCPyV+ Merkel Cell Carcinoma patients.
Read the detailed description
The aim of the study is to test and validate in vitro a cell therapy approach for MCPyV+ Merkel Cell Carcinoma patients.
- Conditions
- Merkel Cell Carcinoma of Skin
- Keywords
- Merkel Cell Carcinoma of Skin
What is being measured
The primary outcome is the main question the study is designed to answer.
Anti-MCPyV functionality
Anti-MCPyV functionality, including cytotoxicity, of T cells obtained after in vitro culture.
Measured: Day 0 and Day 4
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted17 Jan 2025
- Study start27 May 2025
- Primary completionMay 2027 (estimated)
- Study completionMay 2027 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Merkel Cell Carcinoma of SkinStudies of the same condition, open and under way.
- More trials run by Assistance Publique - Hôpitaux de ParisThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 15 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Assistance Publique - Hôpitaux de Paris
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
- Investigators
- Astrid Blom, MD, Principal investigator, Dermato-oncology Department, Ambroise Paré Hospital, APHPYassine Taoufik, MD, PhD, Study director, U1186 INSERM, PAUL BROUSSE Hospital, APHP
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06780475
- Sponsor's protocol ID
- APHP240470
- Other IDs
- 2024-A00643-44
- Acronym
- VIRASKIN
- Status last verified
- Sep 2025
- First submitted
- 13 Jan 2025
- Last updated
- 19 Nov 2025
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 19 Nov 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Validation of in Vitro Method for Anti-MCPyV Immunotherapy on Patients With Merkel Cell Carcinoma of Skin
- ClinicalTrials.gov ID
- NCT06780475
- Acronym / sponsor ID
- VIRASKIN / APHP240470
- Conditions
- Merkel Cell Carcinoma of Skin
- Keywords
- Merkel Cell Carcinoma of Skin
- Study type
- Observational
- Recruitment status
- Recruiting
- Enrolment
- 15 participants (estimated)
- Lead sponsor
- Assistance Publique - Hôpitaux de ParisUniversity, hospital or other
- Collaborators
- Institut National de la Santé Et de la Recherche Médicale, France
- Study start
- 27 May 2025 (actual)
- Primary completion
- May 2027 (estimated)
- Study completion
- May 2027 (estimated)
- First posted
- 17 Jan 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The aim of the study is to test and validate in vitro a cell therapy approach for MCPyV+ Merkel Cell Carcinoma patients.
Detailed description
The aim of the study is to test and validate in vitro a cell therapy approach for MCPyV+ Merkel Cell Carcinoma patients.
Study design
- Observational model
- Cohort
- Time perspective
- Prospective
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- Adult patients of Merkel cell carcinoma of skin, ongoing for local treatment, systemic treatment, complementary treatment or with an active follow-up beside dermatologist.
Key inclusion criteria (4 listed)
- Patients >= 18 years old;
- Diagnosed with Merkel cell carcinoma of skin, ongoing for local treatment, systemic treatment, complementary treatment or an active follow-up;
- Informed for the study and no-opposed for participation;
- Affiliated with a social security scheme or in an equivalent situation.
Key exclusion criteria (4 listed)
- Patients ongoing another interventional clinical trial;
- Patients under guardianship or trusteeship;
- Pregnancy or breastfeed;
- Patients refusal.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
Anti-MCPyV functionality
Time frame: Day 0 and Day 4
Anti-MCPyV functionality, including cytotoxicity, of T cells obtained after in vitro culture.
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 19 Nov 2025.
- Individual participant dataSharing planned: No
Related trials for Merkel Cell Carcinoma of Skin
RecruitingObservational study
Studies of Dermatologic Diseases Biospecimen Acquisition Protocol
Dermatologic Conditions, Healthy Volunteers
Active, not recruitingPhase 1/2
A Beta-only IL-2 ImmunoTherapY Study
Advanced Solid Tumor, Unresectable Solid Tumor
RecruitingPhase 1/2
Immunotherapy in Combination With Prednisone and Sirolimus for Kidney Transplant Recipients With Unresectable or Metastatic Skin Cancer
Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage III Cutaneous Merkel Cell Carcinoma AJCC v8
RecruitingPhase 1/2
A Study to Evaluate ARV-6723 Alone and With Pembrolizumab in Participants With Advanced Solid Tumors
Advanced Solid Tumor
RecruitingPhase 1/2
A Study to Investigate Safety of AZD6750 in Adult Participants With Select Advanced or Metastatic Solid Tumors
Melanoma, Non-small Cell Lung Cancer
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Yassine Taoufik, MD, PhD contact
Astrid Blom, MD principal investigator
Dermato-oncology Department, Ambroise Paré Hospital, APHP
Yassine Taoufik, MD, PhD study director
U1186 INSERM, PAUL BROUSSE Hospital, APHP
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Merkel Cell Carcinoma of Skin, run by Assistance Publique - Hôpitaux de Paris at 1 site in France.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 4 inclusion and 4 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 19 Nov 2025. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in France. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Astrid Blom, MD (+33 (01) 49 09 44 82, astrid.blom@aphp.fr), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Anti-MCPyV functionality (time frame: Day 0 and Day 4). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 19 Nov 2025.